Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options

NCT01737502 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01737502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01737502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
May 14, 2014
Completion date
April 24, 2023
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung carcinoma, lung adenocarcinoma, recurrent non-small cell lung carcinoma, recurrent small cell lung carcinoma, squamous cell lung carcinoma, stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer